Pharmaceutical composition of nanoparticles
View Patent ↗The invention discloses nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein the bioactive agent may include mitofusin 1, mitofusin 2, and/or anti-diabetic compounds.
1. A pharmaceutical composition of nanoparticles, said nanoparticles consisting of positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent comprising mitofusin 1 or mitofusin 2.
2. The pharmaceutical composition of claim 1 , wherein said chitosan is N-trimethyl chitosan, mono-N-carboxymethyl chitosan (MCC), N-palmitoyl chitosan (NPCS), EDTA-chitosan, low molecular weight chitosan, chitosan derivatives, or combinations thereof.
3. The pharmaceutical composition of claim 1 , wherein said nanoparticles are formed via a simple and mild ionic-gelation process.
4. The pharmaceutical composition of claim 1 , wherein said negatively charged substrate is a PGA-complexone conjugate.
5. The pharmaceutical composition of claim 1 , wherein said substrate is selected from the group consisting of γ-PGA, α-PGA, water-soluble salts of PGA, metal salts of PGA, and glycosaminoglycans.
6. The pharmaceutical composition of claim 1 , wherein said nanoparticles are formulated into a tablet or pill configuration.
7. The pharmaceutical composition of claim 6 , wherein said tablet or pill is treated with an enteric coating.
8. The pharmaceutical composition of claim 1 , wherein said nanoparticles are encapsulated in a capsule.
9. The pharmaceutical composition of claim 8 , wherein said capsule further comprises a pharmaceutically acceptable carrier, diluent, or excipient.
10. The pharmaceutical composition of claim 9 , wherein said excipient further comprises at least a solubilizer, bubbling agent, or emulsifier.
11. The pharmaceutical composition of claim 8 , wherein said capsule is treated with an enteric coating.
12. The pharmaceutical composition of claim 8 , wherein said capsule further comprises at least one permeation or absorption enhancer.
13. The pharmaceutical composition of claim 12 , wherein said permeation or absorption enhancer is selected from the group consisting of Ca 2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives.
14. The pharmaceutical composition of claim 8 , wherein said capsule further comprises second nanoparticles, said second nanoparticles consisting of positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent of anti-diabetic compounds.
15. The pharmaceutical composition of claim 1 , wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form.
16. The pharmaceutical composition of claim 1 , wherein said nanoparticles are mixed with trehalose and then freeze-dried, thereby said nanoparticles being in a powder form.
17. The pharmaceutical composition of claim 1 , wherein said zero-charge compound is an absorption or permeation enhancer.
18. The pharmaceutical composition of claim 1 , wherein said at least one bioactive agent further comprises an anti-diabetic compound.
19. The pharmaceutical composition of claim 18 , wherein said anti-diabetic compound is selected from the group consisting of insulin, an insulin analog, GLP-1, a GLP-1 analog, an insulin sensitizer, an insulin secretagogue, an inhibitor of dipeptidyl peptidase 4, metformin, alpha-glucosidase inhibitors, amylin analog, sodium-glucose co-transporter type 2 (SGLT2) inhibitors, benfluorex, tolrestat, and combinations thereof.
20. The pharmaceutical composition of claim 1 , wherein said negatively charged substrate is heparin or low molecular weight heparin.